Nasal mucosal humoral responses to SARS-CoV-2 vaccination priming schedules in the UK: a substudy of the Com-COV single-blind, randomised, non-inferiority trial
In brief
Intramuscular COVID vaccines did not induce new nasal IgA in adults
In a 101-person substudy of adults aged 50 and older, one or two intramuscular vaccine doses showed no evidence of inducing new nasal anti-spike IgA. Nasal IgA increases tracked signs of mucosal virus exposure, not serum vaccine responses, suggesting exposure could confuse assessments of vaccine effects; whether mucosal vaccines can add protection remains to be tested.
- Journal
- The Lancet. Microbe (Q1)
- Published
- 12 November 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Robert H Shaw, Tanya Dinesh, Jennifer Alderson, Sandra Belij-Rammerstorfer, Sagida Bibi, Elizabeth A Clutterbuck, et al.
- PMID
- 43020105
- DOI
- 10.1016/j.lanmic.2026.101560
Why clinicians should know about it
- Picked for Public Health, Environmental and Occupational Health (top studies of the week, 15 November 2026): Randomized vaccine schedules inform population vaccination strategy
Abstract
BACKGROUND: Mucosal surfaces form the first line of defence against respiratory pathogens. Most licensed COVID-19 vaccines are delivered intramuscularly and elicit strong systemic immunity. Whether such vaccines generate locally derived nasal mucosal responses remains uncertain. In this substudy, we aimed to investigate mucosal and systemic antibody responses following different intramuscular SARS-CoV-2 priming vaccination schedules. METHODS: In the Com-COV single-blind, randomised, non-inferiority trial, adults aged 50 years or older who were COVID-19 unvaccinated and SARS-CoV-2 infection-naive were enrolled across eight sites in the UK between Feb 11, 2021, and Feb 26, 2021. Participants were randomised to receive homologous or heterologous vaccination schedules using ChAdOx1 nCoV-19 (ChAd) and BNT162b2 (BNT), administered at either a 28-day or 84-day interval. This substudy collected nasal lining fluid using nasosorption strips in long-interval cohorts. Anti-spike and anti-nucleocapsid IgG and IgA were quantified in serum and nasal samples by electrochemiluminescence immunoassay. Correlations were assessed using Pearson's coefficients. FINDINGS: Mucosal lining fluid samples were collected from 101 participants (mean age 59·1 years [SD 5·0]; 49 [49%] women; 33 [33%] non-White ethnicities). Significant increases in mucosal anti-spike IgA from baseline were seen for ChAd-BNT (geometric mean concentration was 612·8 AU/mL [95% CI 363·6-1032·7]) and BNT-BNT (906·4 AU/mL [619·36-1325·8]). This corresponded to fold rises of 2·78 (1·39-5·54) for ChAd-BNT and 3·11 (1·76-5·50) for BNT-BNT. Mucosal anti-spike IgA trajectories did not mirror vaccination-induced systemic markers, including serum anti-spike IgG (r=0·13, 0·03-0·23, p=0·013). Instead, mucosal anti-spike IgA trajectories correlated with mucosal anti-nucleocapsid IgA (r=0·78, 0·74-0·82, p=5 × 10-77), consistent with mucosal SARS-CoV-2 exposure. Across all schedules, no evidence existed of de novo nasal IgA induction following one or two intramuscular doses, irrespective of baseline serostatus. Observed increases in nasal anti-spike IgA were more consistent with intercurrent mucosal SARS-CoV-2 exposure than direct vaccine effect. Nasal IgG appeared to reflect systemic vaccine responses, whereas SARS-CoV-2 exposure was associated with additional changes in mucosal IgG. INTERPRETATION: Intramuscular immunisation induces robust systemic immunity and remains central to emergency and routine vaccination schedules. However, intramuscular immunisation does not appear to generate de novo local nasal IgA, levels of which have been associated with protection beyond that conferred by serum IgG. Interpretation of vaccine-induced mucosal responses could be confounded by asymptomatic community exposure. Mucosally delivered vaccines are a biologically plausible complementary strategy to enhance protection and reduce transmission, and thus, need further investigation. FUNDING: National Institute for Health Research, the UK Vaccine Taskforce, John Fell Fund, University of Oxford, and Oxfordshire Health Services Research Committee.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.